The American Psychiatric Association’s release of the proposed fifth revision of its billing bible, the Diagnostic and Statistical Manual of Mental Disorders (DSM) fuels University of California’s Dr. Irwin Savodnik’s statement, “The very vocabulary of psychiatry is now defined at all levels by the pharmaceutical industry.”
The American Psychiatric Association yesterday gave the press an advance view of its proposed Diagnostic and Statistical Manual of Mental Disorders, and the reports were highly skeptical. Will Tiger Woods soon be diagnosed with “hypersexual disorder”? He could be if the proposals go into effect. The APA will be accepting comments through April. The news reports barely noted the fact that dozens of psychiatrists who serve on the DSM-V (it’s the fifth edition) task force and working groups have financial ties to the pharmaceutical and medical device industries.
With drug giant GlaxoSmithKline (GSK) now stating it will abandon future antidepressant research, one can only wonder if the U.S. Food and Drug Administration noted GSK’s CEO Andrew Witty’s admission that it is “hard to prove that a depression drug is working” because “patient improvement is measured by subjective mood surveys, and not by the clear-cut blood tests and biological measures used in other diseases.”
The vast majority of Americans are unaware of most of what is included in the Senate and House health care reform bills as they head for reconciliation in the House-Senate Conference. They will be in for a big surprise concerning parity mental health care coverage, covering mental problems comparably to physical problems.
“No matter how DSM V will be written, it will be flawed. There is no psychiatric diagnosis which has an objective measure. At the moment, all diagnoses are clinical diagnoses, meaning they are subjective. This is a field of humility. There is a lot that we do not know. I think there should be an introduction to DSM V which clearly states that this book is a product of work groups…” – Shirah Vollmer, MD